- Since 2019, NSG BioLabs has been a leader in the coworking lab space in the United States. Singaporehas incubated more than 40 biotech companies, among which startups have achieved near-achievement results. 400 million USD Total funding aligned to key business milestones
- NSG BioLabs’ partnership with EnterpriseSG and Merck will enable it to enhance its services to residents with the goal of supporting residents’ innovation and research and development efforts.
- NSG BioLabs also 14.5 million USDIt is led by Celadon Partners, an Asian private equity firm, and ClavystBio, a life sciences investor and venture builder founded by Temasek.
- The new funding will be used to enhance NSG BioLabs’ infrastructure, services and resident benefits, as well as support the expansion of collaborative laboratories and office space.
Singapore, May 7, 2024 /PRNewswire/ — NSG BioLabs, singapore’s Announces partnership with EnterpriseSG, the largest provider of biotech collaborative lab and office space Singapore Government agencies supporting enterprise development and leading science and technology company Merck will strengthen the biotechnology sector by providing necessary resources such as funding, expertise and networks to drive startup research and development (R&D). That’s what I’m aiming for. The company also 14.5 million USD A funding round led by Asian private equity firm Celadon Partners; ClavystBiois a life sciences investor and venture builder founded by Temasek to accelerate the commercialization of breakthrough ideas that impact health. These achievements reaffirm his NSG BioLabs’ strength and expertise in providing high quality, well-managed, turnkey Biosafety Level 2 (BSL-2) certified laboratory and office space. Additionally, these milestones highlight NSG BioLabs’ role as an ecosystem catalyst, providing critical value-added services and networks in fostering scientific innovation and business growth.
Since 2019, NSG BioLabs has created impactful solutions in the health, biomedical, agri-food, and industrial biotechnology sectors in areas such as precision medicine, nucleic acids, AI-enabled drug discovery, and synthetic biology. We have supported innovators. It has the world’s largest collaborative biotechnology laboratory and office footprint. Singapore, coupled with an extensive network of partners, suppliers, and industry experts, NSG BioLabs has supported over 40 companies on a full-time basis. The company’s tenants include multi-billion dollar multinational corporations as well as many promising startups that have achieved important milestones. We were able to raise almost the entire amount of funding from startup residents alone. 400 million USD funding and supported hundreds of jobs.
“NSG BioLabs is committed to supporting innovators and is proud of the contributions we have made. singapore’s A growing biotech ecosystem. Our partnership with EnterpriseSG and Merck demonstrates the importance of a collaborative spirit and we hope to further foster collaboration between other stakeholders to benefit the biotechnology industry. Singapore And that Asia Pacific region,” Said Daphne TheoCEO and Founder of NSG BioLabs, “We are also grateful for the recognition from our strategic investors Celadon Partners and ClavystBio, which supports our commitment to resident innovation through expanded facilities, enhanced value-added services, and expanded valuable industry networking and mentorship.” We look forward to further enhancing our experience. ”
NSG BioLabs has been participating in EnterpriseSG’s Startup SG Accelerator program since 2019[1]. NSG BioLabs is pleased to announce a new partnership with EnterpriseSG to invest in and develop more high-potential biotech startups. In particular, we will expand support to companies with promising innovations in areas such as precision medicine, with the aim of accelerating development and development. Commercialization of such deep tech solutions.
”singapore’s The biotech landscape is evolving significantly, the global startup community is booming, and healthtech deals will double by 2023.[2]. EnterpriseSG will continue to work with industry partners like NSG BioLabs to provide patient capital, infrastructure and expertise to drive the development of new deep technology innovations such as AI-enabled platforms and targeted therapies.This will strengthen you singapore’s Gain an edge in precision medicine and revolutionize healthcare delivery. ” said the doctor. clarice chenEnterpriseSG Healthcare and Biomedical Director.
Furthering its mission to support biotechnology innovators, NSG BioLabs also 14.5 million USD Strategic investment round led by Celadon Partners with participation from ClavystBio. With these new funds, NSG BioLabs plans to enhance its products and services and introduce additional facilities to meet the growing demands of biotech startups and multinational companies. Singapore and Southeast Asia.
“As Southeast Asia The biotechnology sector is experiencing tremendous growth driven by healthcare needs and we are confident that NSG BioLabs’ innovative collaboration model can provide attractive solutions to biotech startups and companies across the region. Masu. NSG BioLabs’ dedication to helping companies accelerate their research and development efforts is commendable. ” Said Donald TanManaging Partner of Celadon Partners.
“ClavystBio is singapore’s Strengthen the life sciences ecosystem through support of NSG BioLabs and its resident startups. This investment strengthens his ClavystBio mission to accelerate breakthrough science for health impact through venture building and strategic partnerships.” said Khoo Shih Ph.D., CEO of ClavystBio..
NSG BioLabs is established and growing as the region’s leading platform, facilitating mutually beneficial connections between residents and other key stakeholders. To further enable residents to develop, grow and scale up, NSG BioLabs has secured a partnership with Merck to provide residents with special access to Merck’s reagents and life sciences instruments. The partnership also includes priority access to biopharmaceutical processing expertise and consulting to scale up production.
Since its inception, NSG BioLabs has been providing BSL-2 certified private and shared laboratory space and offices, equipment, as well as privileged access to service providers and suppliers, and community engagement to support biotech startups and We have supported multinational companies. After the first site opens, November 2019NSG BioLabs has expanded to a second location. August 2021, and recently completed a third site in 2023. Today, NSG BioLabs encompasses a total of 35,000 square feet across his three locations, reinforcing the space as a key hub for biotechnology innovation. As one of the region’s largest private biotech incubators, NSG BioLabs is poised to work with recent partnerships and strategic investors to enhance value-added infrastructure, services and network offerings to our growing community. Masu.
About NSG Bio Lab
Founded with a focus on supporting biotechnology innovation, NSG BioLabs offers state-of-the-art equipment, efficient operations, capital efficiencies, the expertise of a world-class team, and a global network to support life sciences companies. I am. The rich R&D environment includes a fully equipped, certified BSL-2 laboratory and office infrastructure spanning 35,000 square feet in a prime location in Biopolis, Singapore.
NSG BioLabs enables companies ranging from emerging biotech startups to multinational corporations to conduct cutting-edge research and development by providing access to high-quality infrastructure, an extensive partner network, community, and added value. We guarantee that we can do it quickly and efficiently. Build Singapore’s ecosystem, leading to breakthrough biotech ventures and breakthrough technology and product innovations that impact patients.
For more information, please visit: www.nsgbio.com
|
[1] EnterpriseSG’s Startup SG Accelerator supports startup enablers such as incubators and accelerators to foster the development of high-potential startups based in Singapore. |
|
[2] Singapore Venture Funding Status 2023 by DealStreetAsia |
Source NSG BioLabs
